Contract drug production – discover trends and markets with highest revenue potentials Where is outsourced pharma manufacturing heading? Visiongain’s updated study predicts that industry’s revenues from 2016. There you find potentials for sales growth, also exploring trends, technologies, clients’ needs and opportunities.
That new report gives you revenue forecasts to 2026 at overall world market, submarket and national level. Avoid falling behind in data. Instead see what is happening for those medical contracting services – outsourcing and off-shoring – hearing how you can gain and benefit your influence.
Please read on to explore that industry and discover what revenue its future market could generate.
Forecasts to 2026 and other analysis show you commercial prospects From 2016, pharma contract manufacturing organisations (CMOs) hold great potential for small-molecule drugs and biologicals. See what sales expansion is possible.
Besides revenue forecasting to 2026, our new study shows you historical data, growth rates and market shares. See developments in technology and service offerings, finding their meaning. And in our updated report you get 79 tables, 59 charts and interviews with two companies.
With our study you assess trends, demands and sales potentials in the pharma contract and custom manufacturing industry. You see, from 2016, where needs and money exist. Discover the most lucrative pharmaceutical production services, including active compounds and complex drugs.
Gains through understanding those outsourcing services – advantages for your work Avoid struggles to find that business data. Now you can stay ahead in knowledge for contracted drug making, benefiting your research, analysis and decisions. Finding information you need for producing medicines just became quicker and easier.
The following sections explain how you benefit from our new investigation.
Outsourced drug producing – forecasts from 2016 for the world market and submarkets What are the secrets of that industry’s progress? See expected trends there. Along with prediction of the overall world market for outsourced drug production, our report shows you revenue forecasting of 9 submarkets to 2026 at world level: • Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products • Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types • Other applications of outsourced production – other related services.
Our analyses and discussions show you commercial potentials for manufacturing service providers and their technologies. Discover those opportunities for improved production and revenue gains.
With our study you get the forecasting leaders need, benefiting your authority. Our study helps you stay ahead and succeed.
You get geographical revenue predictions, too, finding the best international prospects.
National and regional markets – what outlooks for demand, services and sales? In developed and developing countries, opportunities for pharmaceutical CMOs will occur from 2016, leading to revenue gains. Find the most promising markets.
Our analyses give individual revenue forecasts to 2026 for 12 countries: • United States (US) • Germany, France, the UK, Italy and Spain – EU5 group, also with a regional prediction for the European Union • Brazil, Russia, India and China – BRIC countries • South Korea • Japan.
There you explore progress and outlooks. You assess that drug production sector’s future – hear about developments, also finding their meaning and potential.
That way you find opportunity and assess challenges. Our work explains what the future holds, exploring issues affecting those drug production companies.
Forces affecting pharma CMOs and their clients Our report shows you activities, developments and events affecting that industry and market from 2016, including these influences: • Trends for technology and business in biopharma manufacturing • US and EU regulations, as well as requirements in other countries • Generic Drug User Fee Act and API producing • GMP standards, quality by design (QbD) and virtual pharma companies • Potential for microreactors in outsourced drug making • Backwards integration for generics producers.
Visiongain’s analysis also discusses other trends and needs, including these: • Investment in HPAPI manufacturing facilities • Complex-molecule production, esp. biologics (inc. biosimilars) and orphan medicines • Green technology in contract pharmaceuticals production • Aseptic filling for biological drugs and small-molecule medicines • Production of antibody-drug conjugates (ADCs) and other novel proteins • Lyophilisation, spray drying, hot-melt extrusion and fill-finish services.
With our survey you explore political, economic, social and technological questions, assessing outlooks for business. You examine forces stimulating and restraining that healthcare services industry.
You also see regulatory developments. Discover what that industry’s present and future hold, exploring issues for contract drug makers and clients.
Leading companies and overall 2020 market value – how high can sales go? What is possible for that industry? Our analysis predicts the world market for contract pharma manufacturing will reach $83.9bn in 2020. It will show strong revenue expansion from 2016 to 2026, giving companies high commercial potentials.
In particular our study explores activities, capabilities and results of these companies: • Catalent • Lonza • Evonik Degussa • DPx Holdings • Teva • Boehringer Ingelheim BioXcellence • Famar • Fareva • Vetter Pharma • Mylan.
There you analyse participants’ results, strengths and outlooks. You also gain two interviews with other authorities, our discussions with Lonza and CordenPharma.
So discover what companies in that industry do and say, helping you stay ahead in knowledge and succeed.
7 Main Ways Pharmaceutical Contract Manufacturing 2016-2026 helps – gain data found nowhere else Our new investigation helps you in these seven main ways, benefiting your research, plans, decisions and presentations: • Revenues to 2026 for outsourced drug production at overall world level – explore prospects for technologies, investments, sales and contracts • Prospects of 9 service submarkets – discover the revenue generating potentials of services that custom pharma manufacturing organisations offer • Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia – investigate developed and developing countries’ potentials • Outlooks for established and rising contract drug producers – assess portfolios, results, deals and outlooks, also with 10 company profiles • Clients’ needs – explore production requirements of drug companies, assessing opportunities in serving drug developers, producers and marketers • Analysis of what stimulates and restrains the contract drug production market – explore that industry’s trends, helping you compete and succeed • Interviews with companies and other industry news – discover what that industry’s participants think, say and do, helping you stay ahead.
That report, by our in-house analysts in the UK, benefits your reputation for knowledge, helping you succeed. Gain analysis leading companies depend on.
Data found nowhere else, helping your research, assessments and planning Our new investigation gives you independent analysis. You receive business intelligence found only in our work. With that study you are less likely to fall behind in data or miss opportunity. Instead discover what the future holds for your business.
That way discover where prospects and money exist. Our report’s purpose is to benefit your research, analysis and decisions, also saving you time and effort.
Outsourced manufacturing of pharmaceuticals – explore that industry’s future Our new study is for everyone investigating production of small-molecule medicines and biological drugs. There you find revenue forecasting from 2016, seeing trends, developments and discussions. Avoid missing out – please get our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Pharmaceutical Contract Manufacturing Market Segmentation 1.2 Global Pharmaceutical Contract Manufacturing Market Overview 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Introduction to Pharmaceutical Contract Manufacturing 2.1 What is Pharmaceutical Contract Manufacturing? 2.2 The Benefits of Outsourcing in the Pharmaceutical Market 2.3 Pharmaceutical Contract Manufacturing Services 2.4 Strategy and Tactics: The Importance of Outsourcing Wisely 2.5 Trends in Contract Manufacturing, 2016-2026 2.6 Pharmaceutical Contract Manufacturing: Market Segmentation
3. Pharmaceutical Contract Manufacturing: World Market 2015-2026 3.1 Pharmaceutical Contract Manufacturing Market: Historical Performance 2012-2014 3.1.1 Contract Manufacturing is the Most Mature Pharma Outsourcing Sector 3.1.2 The Pharma Contract Manufacturing Market by Sector 2014 3.2 Pharma Contract Manufacturing: Overall Market Forecast 2015-2026 3.2.1 Changing Submarket Shares by Segment 2015-2026 3.2.2 Drivers for Growth in the Contract Manufacturing Market to 2026 3.2.3 Generics: A Driver or Restraint? 3.2.4 Other Contract Manufacturing Services Submarket: Outlook and Forecast 2014-2016 3.2.4.1 Increasing Demand for Formulation Development Services
4. The Contract API Manufacturing Services Submarket 2015-2026 4.1 The Contract API Manufacturing Submarket 2014 4.1.1 Chemical APIs Will Experience Resurgence After the Shift of Focus to Biological APIs 4.1.2 The API Manufacturing Submarket by Sector 2014 4.2 The Contract API Manufacturing Submarket: Outlook and Forecast 2015-2026 4.2.1 Drivers for Growth in the API Submarket to 2026 4.2.2 The Potential for Microreactors in Commercial Manufacturing to 2026 4.2.3 How Will New EU Regulations Impact the API Manufacturing Submarket? 4.2.4 Contract API Manufacturing Submarket Restraint 2016-2026 4.2.4.1 Backwards Integration for Generics Manufacturers 4.3 The Contract Generic API Manufacturing Submarket 2015-2026 4.3.1 The Contract Generic API Manufacturing Submarket Forecast 2015-2026 4.3.2 The Contract Generic API Manufacturing Submarket Drivers and Restraints to 2026 4.3.2.1 The US Generic Drug User Fee Act and API Manufacturing 4.4 The Contract HPAPI Manufacturing Submarket 2015-2026 4.4.1 Challenges and Opportunities in High Containment Manufacturing 4.4.2 Company Investment into HPAPI Manufacturing Facilities: Growth Increases in the HPAPI Manufacturing Sector 4.4.3 The Contract HPAPI Manufacturing Submarket Forecast 2015-2026 4.4.4 The Contract HPAPI Manufacturing Submarket Drivers and Restraints to 2026
5. The Contract FDF Manufacturing Services Submarket 2015-2026 5.1 The Contract FDF Manufacturing Submarket 2014 5.1.1 Solid Dosage Manufacturing Leads the Market 5.1.2 CMOs Report High Demand for Softgel Formulations 5.2 The Contract FDF Manufacturing Submarket Forecast 2015-2026 5.2.1 Complex Molecule Manufacturing Will Drive Growth to 2026 5.2.2 What Will Restrain Growth in FDF Outsourcing? 5.3 The Contract Solid Dosage Manufacturing Submarket 2015-2026 5.3.1 How Will Revenue for Solid Dosage Manufacturing Grow to 2026? 5.3.2 The Solid Dosage Manufacturing Submarket Drivers and Restraints 2016-2026 5.3.2.1 Will Product Reformulation Drive Growth to 2026? 5.4 The Contract Injectable Dosage Manufacturing Submarket 2015-2026 5.4.1 The Contract Injectable Dosage Manufacturing Submarket Forecast 2015-2026 5.4.1.1 Drug Shortages Offer Opportunity to CMOs in the Short-Term 5.4.2 Demand for Biopharma Manufacturing Will Drive Growth 2016-2026 5.4.2.1 Interest in Antibody-Drug Conjugate Development Is Growing 5.4.2.2 Challenges in Manufacturing Antibody-Drug Conjugates 5.4.3 Lyophilisation and Aseptic Filling Demand Will Rise 5.4.3.1 Will Spray Drying Replace Lyophilisation in FDF Manufacturing?
6. Leading National Markets for Pharmaceutical Contract Manufacturing 2015-2026 6.1 Leading National Markets for Pharmaceutical Contract Manufacturing 2014 6.1.1 Challenges in Assessing the Market: Supply versus Demand 6.1.2 Leading National Pharmaceutical Contract Manufacturing Markets: Revenue Forecasts 2015-2026 6.1.3 Pharmaceutical Manufacturing in the US: Regulatory Oversight 2014 6.1.4 Controlling Foreign Manufacturing Sites 6.1.5 What Impact Will the GDUFA 2012 Have on Foreign Manufacturing? 6.1.6 Outsourcing and US Manufacturing Regulations 6.1.7 Increased Demand for Domestic API Manufacturing? 6.2 The US Contract Manufacturing Market Forecast 2015-2026 6.3 Outlook for Pharmaceutical Contract Manufacturing in the EU 6.3.1 The EU is the Leading Destination for Pharmaceutical Contract Manufacturing 6.3.2 Regulatory Aspects of Pharma Manufacturing in the EU 6.3.2.1 The European Commission Amends Annex 16 6.3.2.2 The Falsified Medicine Directive: Controlling API Imports 6.3.3 Biopharma Manufacturing Demand Will Rise to 2026 6.3.4 The EU Contract Manufacturing Market Forecast 2015-2026 6.3.5 Germany: The Leading EU Destination for API and FDF Manufacturing 6.3.5.1 Demand for Contract Manufacturing in Germany: Revenue Forecast 2015-2026 6.3.6 CMOs Account for a Third of Manufacturing Sites in France 6.3.6.1 French Pharma Contract Manufacturing Market Forecast 2015-2026 6.3.7 Italy: Strong API Manufacturing Traditions 6.3.7.1 Revenue Forecast for the Italian Pharma Contract Manufacturing Market 2015-2026 6.3.8 Spain: How Will Demand for Manufacturing Services Grow to 2026? 6.3.9 UK: Pharmaceutical Contract Manufacturing Market Forecast 2015-2026 6.4 Pharma Contract Manufacturing in Japan to 2026 6.4.1 Pharmaceutical Manufacturing Regulations in Japan 6.4.1.1 The Pharmaceutical Affairs Law 6.4.2 Greater API Outsourcing to Drive Japanese Market Growth to 2026 In Spite of Currency Devaluation Weakening the Economy
7. Leading Emerging Markets for Pharmaceutical Contract Manufacturing 2015-2026 7.1 Pharmaceutical Contract Manufacturing in Developing Countries 7.1.1 Outsourcing to Emerging National Markets from Developed Markets 7.1.1.1 Demand Will Increase for Services in India and China 7.1.2 Domestic Demand for Pharmaceutical Contract Manufacturing Services 7.1.3 Pharmaceutical Contract Manufacturing: Leading Emerging National Market Forecasts 2015-2026 7.2 Chinese Demand for Pharma Contract Manufacturing Services 2015-2026 7.2.1 Improved Manufacturing Regulations in China 7.2.1.1 New Regulations for Excipients and Guidance for API Manufacturing 2012-2013 7.2.1.2 What Are the Consequences to Stricter Manufacturing Regulations in China? 7.2.2 Chinese CMOs Are Investing in Biopharma Manufacturing 7.2.3 China Pharma Contract Manufacturing Market Forecast 2015-2026 7.3 India: CMOs with Strong Infrastructure and Growing Expertise 7.3.1 Regulatory Outlook for Indian Pharma Manufacturing 7.3.1.1 Stricter Quality Standards to Ensure Compliance with EU Rules 7.3.2 Domestic Manufacturing Dominates the Indian Pharma Market 7.3.3 Demand for Contract Manufacturing in India: Market Forecast 2015-2026 7.4 Brazil: Contract Manufacturing Outlook 2015-2026 7.4.1 Pharmaceutical Manufacturing Regulations in Brazil 7.4.1.1 New Guidelines and Regulations Proposed 2012-2013 7.4.2 Brazil Imports Most of its APIs 7.4.3 Brazil: Pharma Contract Manufacturing Market Forecast 2015-2026 7.5 The Russian Pharma Contract Manufacturing Market 2015-2026 7.5.1 Pharma Manufacturing Regulations in Russia 7.5.1.1 Compliance with GMP in Russia 7.5.2 How Will Demand for Contract Manufacturing Grow in Russia to 2026? 7.6 South Korea: Government Supported Growth 7.6.1 South Korea: Strict GMP Regulations 7.6.2 South Korea: Pharma Contract Manufacturing Market Forecast 2015-2026
8. Leading Companies in the Pharmaceutical Contract Manufacturing Market 8.1 Leading CMOs in the Pharmaceutical Contract Manufacturing Market 8.2 Catalent: Leading CMO 8.2.1 Multiple Expansions and Increased Focus on Biologic Manufacturing 8.3 Lonza: Potential to Lead in ADC Manufacturing 8.3.1 Lonza: Expanding its Capacities to Meet Customer Demand for Biologic Manufacturing 8.4 Evonik Degussa: Specialising in Small Molecules 8.4.1 Developments at Evonik Degussa 8.5 DPx Holdings - DSM and Patheon: Recent Merger Has Strengthened Their Position 8.5.1 Increasing Capacity Tactically and Expanding Worldwide 8.6 Teva: The World’s Largest API Manufacturer 8.6.1 Will Teva Expand into Emerging Markets? 8.7 Boehringer Ingelheim BioXcellence: Boehringer’s Biopharma Manufacturing Division 8.7.1 Adding New Services for Growth 8.8 Famar: A Possible Candidate for Acquisition 8.9 Fareva: A Strategic Shift from Acquisition to Increase in Capacity 8.10 Vetter Pharma: Specialists in Aseptic Filling, Lyophilisation and Siliconisation 8.10.1 Vetter’s Growth: Increasing in Capacity and Market Expansion 8.11 Mylan: A World Leader in Generics Manufacturing
9. Pharmaceutical Contract Manufacturing Industry Trends: Qualitative Analysis from a CMO Perspective 2016-2026 9.1 Pharma Contract Manufacturing Market: Strengths and Weaknesses from a CMO Perspective 2016-2026 9.2 Pharma Contract Manufacturing Market: Opportunities and Threats from a CMO Perspective 2016-2026 9.3 Pharma Contract Manufacturing Market: STEP Analysis 2016-2026 9.3.1 Social Factors 9.3.2 New Technologies Will Drive Market Growth to 2026 9.3.2.1 Advantages of Single-Use Technologies in Biopharma Manufacturing 9.3.2.2 Green Technology in Contract Manufacturing 9.3.2.3 Drug Delivery Trends and CMOs 9.3.2.4 Biologics Are Causing Increased Demand for Lyophilisation 9.3.2.5 Improving Solubility and Stability for Small Molecules 9.3.2.6 Spray Drying as an Advantageous Alternative to Lyophilisation 9.3.2.7 Hot-Melt Extrusion: A Niche Opportunity 9.3.3 Economic Pressures 9.3.3.1 Developed-Market CMOs Facing Competition from Emerging Markets 9.3.4 Political Issues 9.3.4.1 How Will Regulatory Developments Affect CMOs? 9.4 Trends in Drug Development Affecting CMOs to 2026 9.4.1 Orphan Drug Development: Smaller Manufacturing Capacities 9.4.2 Complex Biologics: Interest in ADCs is Increasing 9.4.3 How Will Biosimilar Market Growth Affect CMOs? 9.4.4 The Future of Small Molecule Outsourcing 9.5 How Will CMOs Expand in the Coming 10 Years? 9.5.1 CMO Consolidation Will Increase 9.5.2 There Will Be More Manufacturing Facilities Available for Acquisition 9.6 Developments in the Manufacturing Process 2016-2026 9.6.1 Rising Interest from Companies in Quality by Design (QbD) 9.6.2 A Move Towards Continuous Manufacturing
10. Pharmaceutical Contract Manufacturing Trends: Qualitative Analysis of the Pharmaceutical Contract Manufacturing Market from a Client Perspective 2016-2026 10.1 Pharma Contract Manufacturing Market: Strengths and Weaknesses from a Client Perspective 2016-2026 10.2 Pharma Contract Manufacturing Market: Opportunities and Threats from a Client Perspective 2016-2026 10.3 Important Aspects of the Outsourcing Decision 10.3.1 What Factors Will Influence CMO Selection? 10.3.2 CMO-Pharma Partnering Models 10.3.3 Strategic Partnering 10.3.4 Selecting a Local CMO vs. Offshoring 10.3.5 CMOs in Emerging Markets 10.3.6 Good Communication is Vital for Success 10.3.7 Ensuring Protection in Intellectual Property and Tech Transfer 10.3.8 Regulatory Compliance is a Key Deciding Factor for Pharma Clients 10.3.8.1 Regulatory Bodies and Outsourcing 10.3.8.2 Quality Agreement 10.3.8.3 Global Harmonisation Will Improve Compliance 10.4 Trends in Outsourcing Partnerships 2016-2026 10.4.1 Big Pharma and Outsourced Manufacturing 10.4.2 Small and Virtual Pharma Companies 10.4.3 How Will Biotech Funding Impact the Pharma Contract Manufacturing Industry to 2026?
11. Research Interviews 11.1 Interview with Gordon Bates, SVP Business Unit Head, Chemical and Microbial Manufacturing, Lonza Pharma & Biotech 11.1.1 Lonza’s Pharmaceutical Contract Manufacturing Capabilities and Experience 11.1.2 Upcoming Trends in Drug Development that Will Affect the Pharmaceutical Contract Manufacturing Industry 11.1.3 The Potential of the Emerging Marketplace 11.1.4 Outlook on Qualities Needed For CMO Success 11.1.5 Industry Trends: Changes in the Next Ten Years 11.2 Interview with Dr Michael Quirmbach, VP, Global Sales and Marketing, CordenPharma International 11.2.1 The Range of CDMO Services Available at CordenPharma 11.2.2 CordenPharma’s Systematic Approach Navigates the Challenges of HPAPI Manufacturing 11.2.3 Future Trends in the Developed and Emerging Markets for Contract Manufacturing 11.2.4 Certain Manufacturing Sectors are Primed for Growth While Others Decline 11.2.5 Factors for CDMO Success in the Contract Manufacturing Market
12. Conclusions 12.1 The World Pharmaceutical Contract Manufacturing Market 12.2 Outlook for the Market to 2026 12.2.1 Rising Demand for High Value Services 2016-2026 12.2.2 Demand Will Be Highest Among Developed-Market Clients 12.3 Which New Technologies Will Stimulate Demand to 2026?
AbbVie Actavis ADC Biotechnology Aegerion Pharmaceuticals Aenova Group Aesica Pharma Agência Nacional de Vigilância Sanitária (ANVISA) Agensys Agila Specialties Ajinomoto Althea Inc Alexion Pharmaceuticals Almac Group Althea Technologies AMRI (Albany Molecular Research Inc) API Corporation (APIC) Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM) Aspen Pharmacare Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI) Association of British Pharmaceutical Industry (ABPI) Astellas AstraZeneca Banner Life Sciences Banner Pharmacaps Baring Private Equity Asia Bausch & Lomb Bayer Healthcare Ben Venue Laboratories Bend Research Biogen Idec BioIndustry Association (BIA) Biotest Blackstone Group Boehringer Ingelheim Boehringer Ingelheim BioXcellence Bristol-Myers Squibb Company Bushu Pharmaceuticals Cambrex Cambridge Major Laboratories Catalent Pharma Solutions Cedarburg Hauser Cell Therapy Catapult Celldex Therapeutics Celltrion Cenexi Central Drugs Standard Control Organization (CDSCO) Chemisch-Pharmazeutisches Laboratorium Ravensburg Chemtrix China FDA (CFDA) Cipla Cook Pharmica CordenPharma CTC Bio Daito Pharmaceutical Delpharm Department of Health and Family Welfare Development and Reform Commission (NDRC) Dishman Pharmaceuticals DPx Fine Chemicals DPx Holdings B.V. Dr. Reddy’s Laboratories DSP (DSM Sinochem Pharmaceuticals) Eisai Eli Lilly Esteve Quimica European Commission European Medicines Agency (EMA) Euticals Evonik Degussa Famar Fareva Food and Drug Administration (US FDA) FUJIFILM Diosynth Biotechnologies, Gallus Biopharmaceutical, LLC. G-CON GEA Pharma-Systems Genentech GlaxoSmithKline (GSK) Granules India Haupt Pharma Hexal Hospira Hospira One2One ImmunoGen Immunomedics Indian Drug Manufacturer’s Association (IDMA) Indian Pharmaceutical Alliance Innovent Biologics International Society of Pharmaceutical Engineering (IPSE) IRIX Pharmaceuticals Janssen JK Pharmaceutical Johnson & Johnson Knowledge Transfer Network (KTN) Korea Food and Drug Administration (KFDA) Korea Pharmaceutical Manufacturer’s Association (KPMA) Lonza Lupin Marinopoulos Group Matrix Laboratories Medice Medichem Medicines and Healthcare Products Regulatory Agency (MHRA) Medicines Manufacturing Industry Partnership (MMIP) Merck & Co. Micron Technologies Millennium Ministry of Health (MOH) Ministry of Health, Labor and Welfare (MHLW) Ministry of Industry and Information Technology (MIIT) Mitsui & Co Momenta Pharmaceuticals Mylan Neuland Laboratories NICE Insight NPS Pharmaceuticals Nycomed Orchid Chemicals & Pharmaceuticals Oxford Biomedica Patheon Patheon Biologics Pfizer Pharmaceutical and Medical Devices Agency (PMDA) Pharmapak Technologies Piramal Pharma Solutions Progenics Quintiles Recepta Biopharma Recipharm Redwood Bioscience Rentschler Biotechnologie Roche Royal DSM SAFC SafeBridge Samsung Bioepis Samsung BioLogics Sandoz Sanofi Seattle Genetics Shandong Xinhua ShangPharma Shire Siegfried AG Sigmar Italia SMS Pharmaceuticals Solvias AG Speedel Stada Stem CentRx Stevenage Bioscience Catalyst Takeda Temmler Group Teva API Thermo Fisher Scientific UMN Pharma UNIGEN Valeant Pharmaceuticals Valerion Therapeutics, LLC. Vetter Pharma-Fertigung GmbH Vivante GMP Solutions West Pharmaceutical Services World Health Organization (WHO) WuXi PharmaTech Zhangjiang Biotech & Pharmaceutical Base Company Zhejiang Jiang Yuan Tang Biotechnology
Download sample pages
Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Pharmaceutical Contract Manufacturing Market 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
